UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1376-4
Program Prior Authorization/Notification
Medication Kerendia® (finerenone)
P&T Approval Date 12/2021, 12/2022, 1/2024, 10/2024
Effective Date 2/1/2025
1. Background:
Kerendia (finerenone) is indicated to reduce the risk of sustained estimated glomerular filtration
rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial
infarction, and hospitalization for heart failure in adult patients with chronic kidney disease
(CKD) associated with type 2 diabetes (T2D).
2. Coverage Criteriaa:
A. Initial Authorization
1. Kerendia will be approved based on all of the following criteria:
a. Diagnosis of chronic kidney disease (CKD) associated with type 2 diabetes (T2D)
-AND–
b. Both of the following:
1) Urinary albumin-to-creatinine ratio (UACR) of greater than or equal to 30 mg/g
-AND-
2) An eGFR of greater than or equal to 25 mL/min/1.73 m2
-AND-
c. Used to reduce the risk of any of the following:
1) Sustained eGFR decline
2) End-stage kidney disease
3) Cardiovascular death
4) Non-fatal myocardial infarction
5) Hospitalization for heart failure
Authorization will be issued for 12 months
© 2024 UnitedHealthcare Services Inc.
1
B. Reauthorization
1. Kerendia will be approved based on the following criterion:
a. Documentation of positive clinical response to therapy
Authorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits or Prior Authorization/Medical Necessity may be in place.
4. References:
1. Kerendia [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.
September 2022.
2. Bakris, GL, Agarwal R, Anker SD, Effect of Finerenone on Chronic Kidney Disease
Outcomes in Type 2 Diabetes. NEJM. 2020; 383:2219-29.
3. de Boer, IH, Khunti, K, Sadusky, T, et al. Diabetes Management in Chronic Kidney
Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney
Disease: Improving Global Outcomes (KDIGO). Diabetes Care 2022.
4. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic
Kidney Disease. Kidney International. 2024 (105): S114-314
Program Prior Authorization/Notification – Kerendia
Change Control
Date Change
12/2021 New program
12/2022 Based on updated guidelines modified UACR to greater than or equal to
30 mg/g and eGFR to greater than or equal to 25 mL/min/1.73 m2 for
diagnosis of chronic kidney disease and updated policy to change the
reduction risk criteria from all to any. Increased the initial authorization
to 6 months. Updated references.
1/2024 Annual review. Updated references.
10/2024 Updated diagnosis language. Updated references.
© 2024 UnitedHealthcare Services Inc.
2